COMMUNIQUÉS West-GlobeNewswire

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
21/09/2026
Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders $4 million registered direct [...]
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
21/09/2026
Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution DELRAY BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- PetMed Express, [...]
Novo Nordisk A/S - share repurchase programme
21/09/2026
Bagsværd, Denmark, 21 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Z Optics Presents Six-Month Clinical Results for the Z+ Virtual Aperture IOL at ESCRS 2026
21/09/2026
Data presented by Dr. Francisco Sánchez León in London show reliably good uncorrected vision at distance, intermediate and near, in daylight and in low light, with no serious adverse events and every patient free of [...]
STATLIA MATRIX MP Sets New Standard for Multiplex Assay Analysis and QC Automation
21/09/2026
CARLSBAD, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Brendan Bioanalytics has released STATLIA MATRIX MP, a powerful data analysis enterprise software system designed to improve the accuracy, reliability, and efficiency [...]
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
21/09/2026
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage [...]
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
21/09/2026
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib [...]
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
21/09/2026
Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability Findings support continued [...]
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
21/09/2026
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised in full, together [...]
Acentra Health CEO Todd Stottlemyer Named to Virginia 500 Power List for Fifth Consecutive Year
21/09/2026
Recognition underscores the healthcare technology leader’s sustained commitment to Virginia’s business community and improved health outcomes nationwide MCLEAN, Va., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a [...]
BayCare Releases 2025 Physician and Provider Annual Report
21/09/2026
CLEARWATER, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- BayCare Health System today released Vital Impact, its 2025 Physician and Provider Annual Report, highlighting a year of clinical excellence, academic growth and [...]
Guardian Classic Welcomes Wounded Warrior Project as Official Sponsor Ahead of September 28 Charity Golf Tournament
21/09/2026
Two mission-driven nonprofit organizations team up to support active-duty, veterans, first responders and their families as the Guardian Classic enters its final days of registration and fundraising SAN DIEGO, Sept. 21 [...]
R3 Vascular Appoints Lisa Wipperman Heine to its Board of Directors
21/09/2026
Brings more than three decades of experience leading innovation across the medical technology industry MOUNTAIN VIEW, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to [...]
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
21/09/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder [...]
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
21/09/2026
Johnson & Johnson introduces the first IL-23R targeted oral peptide that can deliver skin clearance and a favourable safety profile in a once-daily pill. 1,2 ICOTYDE™ (icotrokinra) offers an innovative new option [...]
Transactions under Novonesis’ share buyback program
21/09/2026
Please read the announcement in PDF Attachment 2026_18_Share_buyback
Siemens Healthineers and Novo Join Forces to Advance Care for People Living with MASLD and MASH
21/09/2026
Tarrytown, New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- People most at risk for MASLD/MASH remain largely unaware of the disease and its wider health risks Patients facing this metabolic condition benefit from [...]
Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
21/09/2026
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb study of opamtistomig [...]
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
21/09/2026
Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]

Pages